Sorry, you need to enable JavaScript to visit this website.

VTE Platform - DVT & PE | XARELTO® (rivaroxaban) HCP

XARELTO®: Venous thromboembolism (VTE) platform and condition-specific dosing

XARELTO®: Venous thromboembolism (VTE) platform and
condition-specific dosing

XARELTO® treats and helps protect against DVT/PE wherever your patients need itinpatient and outpatient*1-7

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*The decision regarding initiation setting should be based on the prescriber’s clinical judgment.

Administer 6 to 10 hours after surgery once hemostasis has been established.

Avoid use in patients with CrCl <15 mL/min.

§Discontinue XARELTO® in patients who develop acute renal failure while on treatment.

ǁCalculate CrCl based on actual weight.

Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).

CrCl = creatinine clearance; DVT = deep vein thrombosis; HCP = healthcare professional; LTC = long-term care; PE = pulmonary embolism; VTE = venous thromboembolism.